Amgen Lumakras/Vectibix combo shows promise in phase 1 trial in colorectal cancer
Amgen (NASDAQ:AMGN) said Lumakras in combination with its other drug Vectibix showed encouraging efficacy and safety in certain patients with colorectal cancer in a phase 1b study called CodeBreaK 101.
In total, 40 patients with heavily pre-treated (median of two prior lines of therapy) KRAS G12C-mutated chemo-refractory (resistant) metastatic colorectal cancer (mCRC) were enrolled in the dose expansion group receiving Lumakras (sotorasib) and Vectibix combo, the company said in a Sept. 12 press release.

Amgen said Overall, the confirmed objective response rate (ORR) was 30% in patients with chemo-refractory mCRC.
Disease control was seen in 37 patients with a median progression free survival (PFS - length of time during/after therapy that a patient lives with the disease without it getting worse) of 5.7 months.
Tumor shrinkage of any magnitude was seen in 88% of the patients, the company added.
Amgen noted that Treatment-related adverse events (TRAEs) reported with the combination were consistent with known safety profiles of the individual drugs.
In August it was reported that Lumakras led to a higher incidence of severe liver side effects in combination with immunotherapies, as per data from a phase 1 trial.